Evidence map›Paper›PMID 41087987›Full record

ArticleBMC neurology2025

Delayed emergence of parkinson's disease after reversible manganese-induced parkinsonism: a case report.

Hae-Won Shin

Abstract readCase Reports
In one paragraph

Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hae-Won ShinDepartment of Neurology, Chung-Ang University College of Medicine, Heukseok-ro 105, Dongjak-gu, Seoul, 156-755, South Korea. shinhw@cau.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic manganese (Mn) exposure, particularly in occupational settings such as welding, can lead to Mn-induced parkinsonism, a condition typically considered reversible and distinct from idiopathic Parkinson's disease (PD). However, the neurotoxic effects of Mn may contribute to or accelerate dopaminergic degeneration in susceptible individuals. CASE PRESENTATION: We report the case of a 53-year-old male welder who initially presented with symmetrical parkinsonism and characteristic T1 hyperintensities in the globus pallidus in Brain MRI, consistent with Mn-induced parkinsonism. Symptoms and Brain MRI abnormalities fully resolved one year after cessation of Mn exposure. Three years later, the patient developed new, progressive, and asymmetric parkinsonian symptoms, including a unilateral resting tremor and bradykinesia. 18- fluoropropyl-2β-carbomethoxy-3β-4-iodophenyl nortropane positron emission tomography imaging demonstrated a marked reduction in striatal dopamine transporter uptake, and the patient responded well to levodopa, confirming the diagnosis of idiopathic PD.

conclusionsThis case illustrates a rare longitudinal transition from reversible Mn-induced parkinsonism to idiopathic PD, suggesting that prior Mn exposure may act as a precipitating or accelerating factor for PD pathogenesis. Functional neuroimaging is critical for differentiating between these two syndromes. This report underscores the importance of long-term neurological follow-up in patients with occupational Mn exposure and supports the hypothesis that environmental toxins can contribute to neurodegenerative processes.

Indexed as

ManganeseManganese PoisoningParkinson DiseaseParkinson Disease, SecondaryParkinsonian DisordersHumansMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographyWeldingManganeseDopamine transporter imageManganeseParkinson’s disease

Identifiers

PMID41087987
PMCPMC12522976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.